Meta description: A regulatory update on the MDT 0123 trial in Japan addresses spine degeneration and deformity and notes the study status as not yet recruiting. Stakeholders in medical devices and regulatory affairs should monitor for changes.
What changed in the MDT 0123 Japan study?
The source text shows a study conducted in Japan that uses a combination product MDT-0123 with a device labeled ICBG. The trial targets spinal disc degeneration and spinal deformity. The sponsor is listed as Medtronic Spinal and Biologics. The status is not yet recruiting and the ClinicalTrials.gov entry is NCT07414745. This update confirms the existence of a trial plan within the Japanese regulatory environment and indicates the study is in an early stage of development. Readers should expect further details on site initiation, eligibility criteria and timelines as the project progresses.
What is MDT 0123 and what is the device ICBG?
MDT-0123 is described as a combination product and is used together with a device named ICBG in this study. The interventions include both the MDT-0123 combination product and the ICBG device, with Medtronic Spinal and Biologics cited as sponsor. The conditions covered are disc degeneration and spinal deformity in a study located in Japan. The record underlines that this is a product level interaction between a device and a biologic like component, which will require coordination between device and biologics regulatory pathways if the trial moves forward.
What is the regulatory and clinical trial context?
The entry provides a regulatory style record that aligns with medical device practice. It lists the product as a combination product and includes a device type. The not yet recruiting status indicates no patient enrollment at this time. The information is sourced from ClinicalTrials.gov and is subject to change as the trial progresses. Stakeholders should monitor for updates on any amendments to the trial description, changes in site list, and eventual initiation notice. The record suggests a plan that will require ongoing documentation for safety, performance and compliance with MDR principles as defined by regional authorities.
What happens next and what should readers watch?
Expect updates on site initiation and any regulatory submissions. Readers should watch for changes in the recruiting status and any amendments to the trial design. The sponsor and trial team will post updates on the ClinicalTrials.gov entry and may provide additional materials for regulatory filings. The not yet recruiting status means details on patient eligibility and timelines will come later. Industry observers should also track whether the trial results may inform future device class decisions or combination product labeling that could affect access to care and patient outcomes in the region.
FAQ
- 1. What is MDT 0123? A combination product studied with a device called ICBG for spine indications, specifically disc degeneration and deformity.
- 2. Where is the trial located? In Japan, as listed in the entry.
- 3. What does not yet recruiting mean? It indicates that the trial has not started recruiting participants yet.
- 4. Where can I find official information? The ClinicalTrials.gov page provides the official record and current status.
Recap and implications for readers
The report confirms a study in Japan involving a MDT 0123 combination product with ICBG for spine conditions. The status not yet recruiting suggests timelines will depend on site readiness and regulatory review. Industry professionals should monitor the ClinicalTrials.gov entry for updates and prepare to adapt regulatory and quality processes as information evolves. The involvement of a major sponsor and a specified device indicates a path that could influence future regulatory expectations for similar combinations in the spine field. Readers should prepare to assess potential changes to labeling, risk management documentation, and post market plans if the study advances toward enrollment and eventual data generation.
Disclaimer: This content is for professional information only and does not constitute legal advice. Consult qualified regulatory counsel for guidance specific to your situation.
For full information about the announcement, see the link below.
On the next line place the link as a full URL.
https://clinicaltrials.gov/study/NCT07414745?term=medical+device